首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

2051184

抗體藥物複合體(ADC) 市場：按產品類型、連接子類型、應用、銷售管道和地區分類

Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，抗體藥物複合體（ADC）市場規模將達到80.2億美元，到2033年將達到205.6億美元。預計從2026年到2033年，其複合年成長率將達到14.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	80.2億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	14.40%	2033年市場規模預測：	205.6億美元

抗體藥物複合體（ADC）是標靶治療，可將抗癌藥物遞送至癌細胞。抗體藥物複合體的作用機轉（MOA）相對簡單。一部分抗體藥物複合體靜脈注射，與癌細胞表面的標靶抗原結合，並被細胞攝取。被攝取的囊泡與其他囊泡融合，進入內核內體-溶小體路徑。在溶小體中，蛋白酶分解單株抗體，釋放活性成分。活性成分隨後穿過溶小體膜，進入細胞質和細胞核，與標靶分子結合，誘導細胞死亡。

市場動態

市場參與企業正積極進行研發活動，這有望在預測期內推動全球抗體藥物複合體（ADC）市場的成長。例如，2022年4月5日，商業性成功的腫瘤生物技術公司Exelixis宣布，美國食品食品藥物管理局（FDA）已接受其進行性固態腫瘤臨床實驗（IND），評估XB002在晚期實體瘤患者中的安全性、耐受性、藥物動力學和初步抗腫瘤活性。作為一種新一代組織因子標靶抗體藥物複合體（ADC），與傳統的組織因子標靶ADC相比，XB002有望具有更高的治療指數和更優的安全性。

市場相關人員正著力於策略合作與協議，預計將推動全球抗體藥物複合體（ADC）市場的成長。例如，2022年6月17日，全球領先的研髮型製藥公司衛材株式會社（Eisai）和全球生物製藥公司百時美施貴寶（Bristol-Myers Squibb）宣布，雙方已達成一項全球獨家戰略合作協議，共同開發和商業化抗體藥物複合體（ADC）MORAb-202。

市場參與者和政府機構正透過收購和合作等策略擴大其全球影響力，預計將推動全球抗體藥物複合體（ADC）市場的成長。例如，2021年9月13日，以研發為基礎的生物製藥公司吉利德科學公司（Gilead Sciences）與新一代抗體藥物偶聯物（ADC）技術領域的領導者Immunomedics公司宣布達成最終協議，吉利德將以每股88美元的現金收購Immunomedics。根據協議條款，吉利德將收購乳癌（ First-in-Class抗體藥物複合體，於2021年4月獲得美國食品藥物管理局（FDA）加速核准，用於治療轉移性三陰性乳癌（mTNBC）成人患者。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及主要參與者採取的競爭策略。
本報告根據以下參數對全球抗體藥物複合體(ADC) 市場的主要參與者進行了分析：公司概況、財務業績、產品系列、企業發展區域、分銷策略、主要發展和策略以及未來計劃。
透過利用本報告中的見解，企業負責人和經營團隊將能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份全球抗體藥物複合體(ADC) 市場報告針對產業內的各種相關人員，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球抗體藥物複合體市場中使用的各種策略矩陣，更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

公司簡介
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics（Suzhou）Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

第10章

參考
調查方法

簡介目錄

Product Code: CMI181

Antibody Drug Conjugates Market is estimated to be valued at USD 8.02 Bn in 2026 and is expected to reach USD 20.56 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 8.02 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	14.40%	2033 Value Projection:	USD 20.56 Bn

Antibody Drug Conjugates (ADCs) are targeted medicines that deliver chemotherapy drugs to cancer cells. The mechanism of action (MOA) of antibody-drug conjugates is fairly straightforward. When a portion of the antibody-drug conjugate is administered intravenously and binds to a target antigen on the cell surface of the tumor cell, the complex is internalized. Internalized vesicles fuse with other vesicles and enter the endosome-lysosome pathway after internalization. In the lysosome, proteases digest the monoclonal antibody to release free payloads, which then cross the lysosome membrane to enter the cytoplasm and/or nucleus, where they bind to the target molecule, causing cell death.

Market Dynamics

Market players are involved in research and development activities, this could contribute to the growth of the global antibody drug conjugates market over the forecast period. For instance, on April 05, 2022, Exelixis, Inc., a commercially successful oncology-focused biotechnology company, announced that the U.S. Food and Drugs Administration (FDA) accepted their Investigational New Drug Application (IND) to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of XB002 in patients with advanced solid tumors. XB002, as a next-generation tissue factor-targeting antibody-drug conjugate (ADC), has the potential for a higher therapeutic index and a better safety profile than earlier-generation tissue factor-targeting ADCs.

Market players are focused on strategic collaborations and agreements, which is expected to propel the growth of the global antibody drug conjugates market. For instance, on June 17, 2022, Eisai Co., Ltd., a leading global R&D-based pharmaceutical company, and Bristol-Myers Squibb Company, a global biopharmaceutical company, announced an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).

Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, which is expected to drive the growth of the global antibody drug conjugates market. For instance, on September 13, 2021, Gilead Sciences, Inc., a research-based biopharmaceutical company, and Immunomedics, a leader in next-generation antibody-drug conjugate (ADC) technology, announced a definitive agreement under which Gilead will acquire Immunomedics for US$ 88.00 per share in cash. Under the terms of agreement, Gilead will be provided with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April 2021, for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC).

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global antibody drug conjugates market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global antibody drug conjugates market

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2026 - 2033)
Adcetris
Kadcyla
Enhertu
Trodelvy
Padcev
Others
Linker Type Insights (Revenue, USD Bn, 2026 - 2033)
Non-cleavable Linker
Cleavable Linker
Application Insights (Revenue, USD Bn, 2026 - 2033)
Blood Cancer
Breast Cancer
Ovary Cancer
Lung Cancer
Skin Cancer
Brain Tumor
Others
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
Hospital Pharmacies
Retail Pharmacies
E-commerce
Regional Insights (Revenue, USD Bn, 2026 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East & Africa
- GCC Countries
- Israel
- South Africa
- Rest of Middle East & Africa
Key Players Insights
AstraZeneca PLC
Daiichi Sankyo Company Limited
Novasep
ADC Therapeutics SA
Alentis Therapeutics AG
F. Hoffmann-La Roche
Gilead Sciences, Inc.
AbbVie Inc.
Biosion USA, Inc.
Astellas Pharma Inc.
Duality Biologics (Suzhou) Co. Ltd.
BioNTech SE
LaNova Medicines Ltd.
Bliss Biopharmaceutical
Eisai Co., Ltd.
ProfoundBio
Pfizer, Inc.
ImmunoGen Inc.
Mersana Therapeutics Inc.
Sorrento Therapeutics Inc.
Oxford BioTherapeutics Ltd
Takeda Pharmaceutical Company Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Linker Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Antibody Drug Conjugates Market, By Product Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adcetris
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Kadcyla
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Besponsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Lumoxiti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Mylotarg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others (Polivy, Lumoxiti, Zynlonta, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

5. Global Antibody Drug Conjugates Market, By Linker Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Non-Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Antibody Drug Conjugates Market, By Application, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Blood Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Breast Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Ovary Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Lung Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Skin Cancer
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Brain Tumor
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Antibody Drug Conjugates Market, By Distribution Channel , 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

8. Global Antibody Drug Conjugates Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- AstraZeneca PLC
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Daiichi Sankyo Company, Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novasep
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ADC Therapeutics SA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alentis Therapeutics AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Gilead Sciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Biosion USA, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Astellas Pharma Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Duality Biologics (Suzhou) Co. Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- BioNTech SE
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- LaNova Medicines Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bliss Biopharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eisai Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ProfoundBio
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ImmunoGen Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mersana Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sorrento Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Oxford BioTherapeutics Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical Company Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies